Cutting-Edge Innovations: Recent Patents in Medicinal Chemistry

References

1. Xiao Y. He Z. Li W. Chen D. Niu X. Yang X. Zeng W. Wang M. Qian Y. Su Y. Luo F. Chen G. Liu J. Sui X. Zhou X. Gao Y. A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy. Nat. Commun. 2025 16 1 1388 10.1038/s41467‑025‑56648‑6 39910101
   [Google Scholar]
2. Sharma A. Narang A. Kumar N. Rana R. Megha; Pooja; Dhir, M.; Gulati, H.K.; Jyoti; Khanna, A.; Singh, J.V.; Kaur, S.; Bedi, P.M.S. CADD based designing and biological evaluation of novel triazole based thiazolidinedione coumarin hybrids as antidiabetic agent. Sci. Rep. 2025 15 1 4302 10.1038/s41598‑025‑88944‑y 39905269
   [Google Scholar]
3. Schallmayer E. Isigkeit L. Elson L. Müller S. Knapp S. Marschner J.A. Merk D. Chemogenomics for steroid hormone receptors (NR3). Commun. Chem. 2025 8 1 29 10.1038/s42004‑025‑01427‑z 39900826
   [Google Scholar]
4. Isaacson S.H. Espay A.J. Pahwa R. Agarwal P. Shill H.A. Hui J. Dashtipour K. Lew M. Qin P. Formella A.E. Ceresoli B.G. LeWitt P.A. Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study. J. Parkinsons Dis. 2025 15 2 10.1177/1877718X241310727
   [Google Scholar]
5. Tepper S. Richard L. Angad, Chh.; Caroline, S; Gregory, P.; Herriot, T. Combined Efficacy and Safety of AXS-07 (MOSEICTM Meloxicam and Rizatriptan) in Two Phase 3 Clinical Trials (P7-12.002). Neurology 2024 102 7 supplement 1 10.1212/WNL.0000000000205655
   [Google Scholar]
6. Osteen J.D. Immani S. Tapley T.L. Indersmitten T. Hurst N.W. Healey T. Aertgeerts K. Negulescu P.A. Lechner S.M. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025 14 2 655 674 10.1007/s40122‑024‑00697‑0 39775738
   [Google Scholar]
7. Shadur B. NasserEddin, A.; Zaidman, I.; Schejter, Y.D.; Even-Or, E.; Berkun, Y.; Meyts, I.; Hmedat, H.; Sulaiman, A.; Tangye, S.G.; Stepensky, P. Successful haematopoietic stem cell transplantation for lrba deficiency with fludarabine, treosulfan, and thiotepa-based conditioning. J. Clin. Immunol. 2025 45 1 3 10.1007/s10875‑024‑01770‑1 39264459
   [Google Scholar]
8. Ritzau O.V. Celltrion receives positive chmp opinion for three biosimilars in the European union. 2024 Available from: https://www.celltrion.com/en-us/company/media-center/press-release/3620
9. Rashid M.A. New Drug Approval Vol. 28 (1). Bangladesh Pharmaceutical Journal 2025 28 1 127 131
   [Google Scholar]